drugset / Trial / NCT05073458

Study of the Efficacy and Safety of Parsaclisib in Participants With Primary Warm Autoimmune Hemolytic Anemia

NCT05073458

Phase 3 Terminated 13 enrolled Incyte Corporation
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of parsaclisib compared with placebo in participants with Primary Warm Autoimmune Hemolytic Anemia (wAIHA),

Timeline

Start
2022-03-15
Primary completion
2023-10-17
Completion
2024-04-29

Drugs

EvaluationDrugModalityDoseRoute
Subject Parsaclisib Small molecule Oral